Cervical Secretions from Women After Depot Medroxyprogesterone Acetate (Depo-Provera) Administration Promote HIV Infectivity Ex Vivo
Viruses · 2025
DOI: 10.3390/v17091283 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Carley Tasker und 3 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Research Institute, Rutgers, New Jersey Medical School, 225 Warren Street, Newark, NJ 07103, USA. Hauptthemen laut MEDLINE: Medroxyprogesterone Acetate, Cervix Uteri, HIV Infections, HIV-1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Depot medroxyprogesterone acetate (Depo-Provera) has been associated with an increased risk of HIV acquisition. We have previously shown that Depo-Provera administration increases immune markers for HIV preference on peripheral and cervical CD4+ T cells but decreases the levels of most immune mediators at vaginal and cervical mucosa. In this study, we determined the effect of cervicovaginal secretions from women before (visit 1), one month (visit 2) and three months (visit 3) after Depo-Provera treatment on HIV infectivity ex vivo. The effect of supernatants from vaginal, endocervical, and rectal swabs and from cervical cytobrush on HIV infectivity were assessed by a single-cycle infection assay using CCR5-using HIV-luciferase reporter viruses. We found that endocervical secretions from women after Depo-Provera treatment promoted HIV infectivity. When analyzing the association between endocervical mediator changes in response to Depo-Provera, available in our previous study, and the changes in HIV infectivity pre- and post-treatment, we found that changes in IL-17 and VEGF were positively associated with changes in HIV infectivity at visit 2 compared with visit 1, whereas changes in RANTES and IL-4 were negatively associated with HIV infectivity. The negative association between RANTES and HIV infectivity was also observed at visit 3 compared with visit 1. Additionally, changes in IL-1α at visit 3 were positively associated with changes in HIV infectivity compared with visit 1. These findings suggest that Depo-Provera may increase the HIV risk by shifting the mucosal milieu that promotes HIV infectivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Public Health Research Institute, Rutgers, New Jersey Medical School, 225 Warren Street, Newark, NJ 07103, USA.
- Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers, New Jersey Medical School, Newark, NJ 07103, USA.
- Department of Obstetrics, Gynecology & Women's Health, Rutgers, New Jersey Medical School, Newark, NJ 07103, USA.
- Department of Obstetrics, Gynecology and Reproductive Health, University Hospital, Newark, NJ 07103, USA.
- Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
ORCID-Profile: Yungtai Lo, Theresa L Chang
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Tasker, C., Roche, N. E., Lo, Y., & Chang, T. L. (2025). Cervical Secretions from Women After Depot Medroxyprogesterone Acetate (Depo-Provera) Administration Promote HIV Infectivity Ex Vivo. Viruses. https://doi.org/10.3390/v17091283
Vancouver
Tasker C, Roche NE, Lo Y, Chang TL. Cervical Secretions from Women After Depot Medroxyprogesterone Acetate (Depo-Provera) Administration Promote HIV Infectivity Ex Vivo. Viruses. 2025. doi:10.3390/v17091283
BibTeX
@article{Tasker2025,
author = {Tasker, Carley and Roche, Natalie E and Lo, Yungtai and Chang, Theresa L},
title = {Cervical Secretions from Women After Depot Medroxyprogesterone Acetate (Depo-Provera) Administration Promote HIV Infectivity Ex Vivo},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17091283}
}
EUVIMED